Changing characteristics of *S. aureus* bacteremia caused by PVL-negative, MRSA strain over 11 years

Eunmi Yang¹, Eunsil Kim², Hyemin Chung¹, Yun Woo Lee¹, Seongman Bae¹,², Jiwon Jung¹, Min Jae Kim¹, Yong Pil Chong¹, Sung-Han Kim¹, Sang-Ho Choi¹, Sang-Oh Lee¹ & Yang Soo Kim¹,²*

Community-acquired methicillin-resistant *Staphylococcus aureus* (MRSA) has emerged as an important cause of infection. We conducted a longitudinal study to evaluate changes in clinical and microbiological characteristics as well as outcomes of sequence type (ST) 72 MRSA bacteremia. We reviewed adult patients enrolled in a prospective cohort with ST72 MRSA bacteremia from August 2008 to December 2018 at Asan Medical Center, Seoul, South Korea. Changes in clinical characteristics, outcomes, and microbiological characteristics of patients over time were evaluated. Generalized linear and linear regression models were used to evaluate changes. Of the 1,760 isolates, 915 (62%) were MRSA bacteremia and 292 (31.9%) were ST72 MRSA. During the study period, the relative risk (RR) of MRSA bacteremia decreased annually by 3.7%; however, among MRSA bacteremia, RR of ST72 MRSA increased annually by 8.5%. Vancomycin minimum inhibitory concentration (MIC) decreased over the study period. Metastatic infection, persistent bacteremia, and recurrence of bacteremia within 12 weeks decreased significantly. There were no significant changes in 30-d and 12-week mortality. Antibiotic susceptibility of ST72 MRSA was evaluated, and the resistance rate to erythromycin decreased significantly. ST72 MRSA incidence increased annually; its vancomycin MIC and erythromycin resistance rate decreased over the 11 years.

Methicillin-resistant *Staphylococcus aureus* (MRSA) is a leading cause of community- and healthcare-associated infections. Hospital-acquired (HA) MRSA and community-acquired (CA) MRSA clones are genetically distinct and their distribution varies in different regions¹. However, in recent years, CA-MRSA has spread and emerged as an important cause of healthcare-associated infection²–⁴. USA300-sequence type (ST)8, a highly prominent Panton-Valentine leucocidin (PVL)-positive CA-MRSA, is the dominant CA-MRSA in North America and is progressively increasing in nosocomial settings⁵.⁶ In Korea, PVL-negative ST72-SCC_Cmec type IV MRSA is a major CA-MRSA strain⁷. The ST72 MRSA strain has also become an important pathogen in hospitals as well as in the community⁸–¹⁰. There have been several studies regarding the prevalence and characteristics of ST72 MRSA, but no previous study has analyzed longitudinal changes in ST72 MRSA. We hypothesized that there were changes in the properties of ST72 MRSA and analyzed changes in the clinical characteristics of patients with ST72 MRSA bacteremia as well as changes in microbiological characteristics and the genotype of ST72 MRSA isolates in our institution over 11 years.

**Materials and methods**

**Study population and design.** This prospective study with a cohort of patients with *S. aureus* bacteremia (SAB) was conducted at the Asan Medical Center, a 2,700-bed tertiary referral center in Seoul, South Korea. From July 2008 to December 2018, all adult patients with SAB were prospectively enrolled in a cohort and observed over a 12-week period. Patients were excluded if they (1) had polymicrobial bacteremia or (2) were discharged before positive blood culture results were available. Of the patients with MRSA bacteremia, only those with ST72 MRSA isolates were included in the study. This study consisted of two sets of analysis; a longitudinal

---

¹Division of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro43-gil, Songpa-gu, Seoul 05505, Republic of Korea. ²Center for Antimicrobial Resistance and Microbial Genetics, University of Ulsan College of Medicine, Seoul, Republic of Korea. ³email: yskim@amc.seoul.kr
analysis to evaluate changes in the clinical characteristics and outcomes of ST72 MRSA bacteremia, and a comparison of clinical characteristics and outcomes in the first 3 years (2008–2010) and final 3 years (2016–2018). We also evaluated subgroup analysis in patients with community-onset and HA infection. Informed consent was obtained from all individual participants included in the research. All methods were performed in accordance with relevant guidelines and regulations. This study was approved by the Asan Medical Center Institutional Review Board.

**Data collection and study definitions.** The following data were recorded: age, gender, demographic characteristics, underlying diseases, severity of underlying disease or condition, bacteremia severity, location of acquisition, initial source of SAB, susceptibility to antibiotics, and clinical outcomes. Acute Physiology and Chronic Health Evaluation II (APACHE II) and Pitt bacteremia scores were used to evaluate the severity of bacteremia, and the Charlson comorbidity index were used to evaluate the severity of comorbid conditions.

Location of acquisition was categorized as CA, healthcare-associated, or HA infection. Catheter-related infection and infective endocarditis were defined in accordance with widely accepted criteria. Prosthetic devices included orthopedic devices, prosthetic valves, cardiovascular electronic devices, and vascular grafts. Septic shock was defined according to the Third International Consensus Definitions for Sepsis and Septic Shock. Persistent bacteremia was defined as bacteremia for ≥ 3 d while receiving appropriate antibiotic therapy. Recurrent bacteremia was defined as the occurrence of SAB within 12 weeks following clinical resolution; 30-day mortality and 12-week mortality mean all-cause deaths within 30 days and 12 weeks after bacteremia, respectively. Infection-attributable mortality was death due to ST72 MRSA infection in a previously healthy individual or when ST72 MRSA infection hastened death in the presence of an underlying medical condition.

**Microbiology analysis.** The first bloodstream isolates from each patient were used for microbiological and molecular assessments. All isolates were confirmed as MRSA by polymerase chain reaction detection of the mecA gene, and multi-locus sequence typing was performed as described elsewhere. The vancomycin minimum inhibitory concentrations (MICs) were determined using a broth microdilution method based on the manufacturer's protocol. Antimicrobial susceptibilities were tested by standard techniques according to the Clinical and Laboratory Standards Institute.

The staphylococcal cassette chromosome mec (SCCmec) type, agr functionality, and spa sequence typing were identified using previously described methods. The agr disfunction was determined by analyzing δ-hemolysin activity as described previously. The assignment of spa type was performed using BIONUMERICS (APPLIED MATHS).

**Statistical analysis.** All variables for each year's clinical characteristics, agr functionality, SCCmec type, and spa type were summarized, and annual changes were analyzed using a generalized linear model. Continuous variables were analyzed using a linear regression model. We compared patients in the first 3 years (2008–2010) and in the final 3 years (2016–2018). Categorical variables were compared using the Chi-squared test or Fisher's exact test, as appropriate. Continuous variables were compared using Student's t test and the Mann–Whitney U-test. A two-tailed p value less than 0.05 was considered significant. All statistical analyses were performed using SPSS software, version 21.0 (IBM Corp., Armonk, NY, USA).

**Ethics approval.** This study was approved by the hospital ethics committee.

**Results**

**Annual change in clinical characteristics and outcomes of ST72 MRSA.** From July 2008 to December 2018, there were 1,760 episodes of SAB, and 915 (62%) were MRSA bacteremia. Among the 915 MRSA isolates, 292 (31.9%) were ST72 MRSA. During the study period, the relative risk (RR) of MRSA bacteremia decreased annually by 3.7% (p < 0.01) and among MRSA bacteremia, the RR of ST72 MRSA increased annually by 8.5% (p < 0.01) (Fig. 1a). Locations of acquisition of ST72 MRSA over an 11-year period are shown in Fig. 1b. The clinical and microbiological characteristics of ST72 MRSA are shown in Table 1. HA bacteremia was found in 49.7% (145/292) of cases and CA bacteremia in 10.3% (30/292) of cases. Most common comorbidities were diabetes mellitus (37.0% [108/292]), solid tumor (36.6% [107/292]), liver cirrhosis (14.4% [42/292]), and end stage renal disease (14.0% [41/292]). The site of acquisition of MRSA bacteremia and underlying diseases did not show significant change during the study period.

There were no significant changes in Charlson comorbidity index, APACHE II score, or Pitt bacteremia score. Characteristics of infection were identified as central venous catheter (CVC)-related infection (19.9% [58/292]), primary bacteremia (14.4% [42/292]), bone and joint infection (11.3% [33/292]), skin and soft tissue infection (8.9% [26/292]), pneumonia (8.2% [24/292]), and infective endocarditis (4.8% [14/292]). The RR of pneumonia increased annually by 15.9% (p = 0.03) (Fig. 2a).

Metastatic infection was found in 19.5% (57/292) of cases and persistent bacteremia in 39.7% (116/292) of cases. Metastatic infection (RR 0.89; p = 0.01) and persistent bacteremia (RR 0.94; p = 0.045) showed significant annual decrease (Fig. 2a). During the study period, 34 (11.6%) patients died within 30 d after the index day and 258 (88.4%) patients survived. There were no significant changes in 30-d and 12-week mortality. Recurrent ST72 MRSA bacteremia occurred in 13 (4.5%) cases and decreased over the study period (RR 0.7; p < 0.01) (Fig. 2b).

**Annual changes in microbiological characteristics and antibiotic susceptibility of ST72 MRSA.** The mean vancomycin MIC was 1.08 mg/L, and this decreased annually by 0.01 (R² = 0.025; p = 0.01).
agr dysfunction was 10.6% (31/292). SCCmecIV was 99.7% (291/292), and most SCCmecIV was SCCmecIVA (86.3%, [251/291]). Common spa types were t324 (47.6% [139/292]), t664 (14.4% [42/292]), and t148 (11.3% [33/292]) (Fig. 3). The proportions of agr dysfunction, SCCmec type, and spa type did not differ over the study period. Antibiotic susceptibility tests were conducted on 10 antibiotics. There was no change in the resistance rate to most antibiotics, but that to erythromycin decreased significantly during the study period (RR 0.89; p < 0.01).

Comparison of ST72 MRSA between the first 3 years and final 3 years of study. In the first 3 years (2008–2010), 296 patients had MRSA bacteremia and 69 (23.3%) of these cases were ST72 MRSA. In the final 3 years (2016–2018), 209 patients had MRSA bacteremia and 88 (42.1%) of these cases were ST72 MRSA. The proportions of ST72 MRSA bacteremia was significantly higher in patients in the final 3 years of study than in those in the first 3 years of study (p < 0.01). Comparisons of the two groups are shown in Table 2. There were no significant differences in the location of acquisition, underlying disease, and characteristics of infection between the two groups. The patients in the first 3 years were more likely to have metastatic infection (33.3% [23/69] vs. 17.0% [15/88], p = 0.02) and persistent bacteremia (55.1% [38/69] vs. 35.2% [31/88], p = 0.01) than patients in the final 3 years. Recurrent bacteremia occurred more frequently in patients in the first 3 years (11.6% [8/69] vs. 0% [0/88], p < 0.01). There was no difference in 30-d and 12-week mortality between the two groups.
| Characteristic                        | Number of patients (%) | Annual change                     | RR (95% CI)   | p value |
|--------------------------------------|------------------------|-----------------------------------|---------------|---------|
| Age (year), median (IQR)             | 64 (53–72)             | NA                                | NA            | NA      |
| Male                                 | 175 (59.9)             | NA                                | NA            | NA      |
| **Place of acquisition**             |                        |                                   |               |         |
| Community-onset                      | 147 (50.3)             | 1.02 (0.97–1.08)                  | 0.47          |         |
| Community-acquired                   | 30 (10.3)              | 0.96 (0.85–1.08)                  | 0.47          |         |
| Healthcare-associated                | 117 (40.1)             | 1.04 (0.98–1.10)                  | 0.24          |         |
| Hospital-acquired                    | 145 (49.7)             | 0.98 (0.93–1.03)                  | 0.47          |         |
| **Underlying disease**               |                        |                                   |               |         |
| Diabetes mellitus                    | 108 (37.0)             | 1.00 (0.94–1.07)                  | 0.94          |         |
| Solid tumor                          | 107 (36.6)             | 1.01 (0.95–1.08)                  | 0.76          |         |
| Liver cirrhosis                      | 42 (14.4)              | 1.08 (0.98–1.20)                  | 0.14          |         |
| End stage renal disease              | 41 (14.0)              | 1.01 (0.91–1.12)                  | 0.86          |         |
| Charlson comorbidity index, median (IQR) | 2 (2–4.8)          | 1.05*                             | 0.30          |         |
| APACHE II, median (IQR)              | 16 (11–20)             | −0.03*                            | 0.83          |         |
| Pitt bacteremia score, median (IQR)  | 1 (0–2)                | −0.01*                            | 0.82          |         |
| Septic shock                         | 33 (11.3)              | 0.96 (0.86–1.07)                  | 0.45          |         |
| Central venous catheter              | 88 (30.1)              | 1.00 (0.93–1.07)                  | 0.93          |         |
| Prosthetic device*                   | 58 (19.9)              | 0.99 (0.91–1.07)                  | 0.75          |         |
| **Characteristics of infection**     |                        |                                   |               |         |
| CVC-related infection                | 58 (19.9)              | 0.94 (0.86–1.03)                  | 0.16          |         |
| Primary bacteremia                   | 42 (14.4)              | 0.98 (0.89–1.09)                  | 0.72          |         |
| Bone and joint infection             | 33 (11.3)              | 0.96 (0.86–1.08)                  | 0.48          |         |
| Skin and soft tissue                 | 26 (8.9)               | 1.08 (0.95–1.23)                  | 0.26          |         |
| Pneumonia                            | 24 (8.2)               | 1.17 (1.02–1.35)                  | 0.03          |         |
| Infective endocarditis               | 14 (4.8)               | 1.01 (0.85–1.20)                  | 0.91          |         |
| Metastatic infection                 | 57 (19.3)              | 0.89 (0.82–0.97)                  | 0.01          |         |
| Persistent bacteremia (≥ 3 d)        | 116 (39.7)             | 0.94 (0.89–1.00)                  | 0.045         |         |
| Recurrent bacteremia within 12 weeks | 13 (4.5)               | 0.70 (0.56–0.89)                  | <0.01         |         |
| 30-d mortality                       | 34 (11.6)              | 1.08 (0.97–1.21)                  | 0.17          |         |
| 12-week mortality                    | 65 (22.3)              | 1.02 (0.94–1.11)                  | 0.60          |         |
| Infection-attributable mortality     | 38 (13.0)              | 1.08 (0.97–1.20)                  | 0.17          |         |
| In-hospital crude mortality          | 39 (13.4)              | 1.05 (0.95–1.17)                  | 0.34          |         |
| Vancomycin MIC (BMD), mean±SD (mg/L)| 1.08±0.20              | −0.01**                           | 0.01          |         |
| agr dysfunction                      | 31 (10.6)              | 1.02 (0.90–1.14)                  | 0.79          |         |
| SCCmec type                          |                        |                                   |               |         |
| SCCmec IV                            | 291 (99.7)             | 1.00 (0.96–1.04)                  | 0.96          |         |
| SCCmec IVa                           | 251/291 (86.3)         | 0.99 (0.95–1.03)                  | 0.64          |         |
| **spa type**                         |                        |                                   |               |         |
| t324                                 | 139 (47.6)             | 0.96 (0.91–1.02)                  | 0.19          |         |
| t664                                 | 42 (14.4)              | 0.96 (0.87–1.06)                  | 0.39          |         |
| t1148                                | 33 (11.3)              | 0.98 (0.88–1.10)                  | 0.72          |         |
| Others                               | 49 (16.8)              | NA                                | NA            |         |
| **Antibiotic resistance**            |                        |                                   |               |         |
| Amoxicillin/Clavulanate              | 271 (92.8)             | 1.00 (0.97–1.04)                  | 0.85          |         |
| Clindamycin                          | 58 (19.9)              | 0.98 (0.90–1.07)                  | 0.68          |         |
| Ciprofloxacin                        | 23 (7.9)               | 1.15 (1.00–1.33)                  | 0.05          |         |
| Erythromycin                         | 75 (25.7)              | 0.89 (0.82–0.96)                  | <0.01         |         |
| Fusidic acid                         | 3 (1.0)                | 1.11 (0.75–1.63)                  | 0.60          |         |
| Gentamicin                           | 39 (13.4)              | 0.95 (0.86–1.06)                  | 0.35          |         |
| Rifampin                             | 5 (1.7)                | 1.12 (0.83–1.51)                  | 0.47          |         |
| Quinupristin/Dalfopristin            | 0                     | NA                                | NA            |         |
| TMP/SMX                              | 2 (0.7)                | 0.85 (0.53–1.39)                  | 0.52          |         |
| Tetracycline                         | 8 (2.7)                | 1.07 (0.85–1.35)                  | 0.58          |         |
Vancomycin MIC of patients in the first 3 years was higher than that in patients in the final 3 years (1.11 mg/L vs. 1.03 mg/L, \( p < 0.01 \)). No significant difference was noted in \textit{agr} dysfunction and \textit{spa} type. When comparing the antibiotic resistance of the two groups, the rates of resistance to erythromycin were significantly higher in patients in the first 3 years (42.0% [29/69] vs. 15.9% [14/88], \( p < 0.01 \)).

Annual changes in clinical characteristics and outcomes of patients with community-onset vs. hospital-acquired infection. We analyzed patients with community-onset and HA infection (Tables 3 and 4). Metastatic infection (RR 0.89; \( p = 0.04 \)) and recurrent bacteremia (RR 0.64; \( p = 0.01 \)) decreased in patients

| Table 1. Annual changes in clinical and microbiological characteristics of 292 patients with sequence type 72 MRSA bacteremia. IQR interquartile range; APACHE II acute physiology and chronic health evaluation II; CVC central venous catheter; MIC minimum inhibitory concentration; BMD broth microdilution method; SCC staphylococcal cassette chromosome; TMP/SMX trimethoprim/sulfamethoxazole. *A linear regression model was used for analysis. \( \dagger \)Prosthetic device included orthopedic devices (14 patients), cardiovascular implantable electronic devices (4 patients), prosthetic valves (11 patients), and vascular grafts (30 patients) in patients with persistent bacteremia. \( \ddagger \)Result of linear regression: \( R^2 = 0.025 \), vancomycin MIC = 22.07 + (− 0.01) × year.

| Year | CRBSI | Primary bacteraemia | Bone and joint infection | Skin and soft tissue infection | Pneumonia | Infective endocarditis | Metastatic infection | Persistent bacteraemia |
|------|-------|---------------------|-------------------------|-----------------------------|-----------|------------------------|---------------------|------------------------|
| 2008 | 0.7   | 0.6                 | 0.4                     | 0.3                         | 0.2       | 0.1                    | 0.0                 | 0.0                    |
| 2009 | 0.6   | 0.5                 | 0.3                     | 0.2                         | 0.1       | 0.1                    | 0.0                 | 0.0                    |
| 2010 | 0.5   | 0.4                 | 0.2                     | 0.1                         | 0.0       | 0.0                    | 0.0                 | 0.0                    |
| 2011 | 0.4   | 0.3                 | 0.1                     | 0.0                         | 0.0       | 0.0                    | 0.0                 | 0.0                    |
| 2012 | 0.3   | 0.2                 | 0.0                     | 0.0                         | 0.0       | 0.0                    | 0.0                 | 0.0                    |
| 2013 | 0.2   | 0.1                 | 0.0                     | 0.0                         | 0.0       | 0.0                    | 0.0                 | 0.0                    |
| 2014 | 0.1   | 0.0                 | 0.0                     | 0.0                         | 0.0       | 0.0                    | 0.0                 | 0.0                    |
| 2015 | 0.0   | 0.0                 | 0.0                     | 0.0                         | 0.0       | 0.0                    | 0.0                 | 0.0                    |
| 2016 | 0.0   | 0.0                 | 0.0                     | 0.0                         | 0.0       | 0.0                    | 0.0                 | 0.0                    |
| 2017 | 0.0   | 0.0                 | 0.0                     | 0.0                         | 0.0       | 0.0                    | 0.0                 | 0.0                    |
| 2018 | 0.0   | 0.0                 | 0.0                     | 0.0                         | 0.0       | 0.0                    | 0.0                 | 0.0                    |

Figure 2. (a) Clinical characteristics of ST72 MRSA bacteremia over the study period. (b) Clinical outcomes of ST72 MRSA bacteremia over the study period. CRBSI, catheter-related blood stream infection.
with community-onset infection, but no change was noted in those with HA infection. The resistance rate to erythromycin decreased significantly during the study period (RR 0.87; \( p = 0.01 \)) in patients with community-onset infection but there was no significant change in those with HA infection. Vancomycin MIC decreased annually by 0.01 (\( R^2 = 0.032; p = 0.03 \)) and resistance rate to ciprofloxacin increased (RR 1.24; \( p = 0.03 \)) in patients with HA infection during the study period.

**Discussion**

In this study, we evaluated the clinical, microbiological, and genotypic changes in ST72 MRSA bacteremia over 11 years. The RR of MRSA bacteremia decreased and among these, the RR of ST72 MRSA increased during the study period. *S. aureus* pneumonia increased. Metastatic infection, persistent bacteremia, and recurrent bacteremia decreased during the study period. The rate of erythromycin resistance decreased significantly over the 11 years.

PVL-negative ST72 MRSA is a major CA-MRSA strain in South Korea and is an important cause of nosocomial infection. The incidence of infections caused by ST72 MRSA is increasing in both community and healthcare settings. Kim et al.\(^6\) reported that ST72 MRSA isolates constituted 34.7% of CA-MRSA infection and 4.2% of HA-MRSA infection. In blood stream infection, 22.5–25.0% of MRSA bacteremia were ST72 MRSA and 21.0% of HA-MRSA bacteremia were ST72 MRSA\(^22,23\). In this study, MRSA bacteremia levels decreased over 11 years, but ST72 MRSA increased significantly. ST72 MRSA levels of patients were significantly higher in the final 3 years than in the first 3 years. A large proportion of ST72 MRSA bacteremia were HA infections.

Previous studies have reported conflicting results regarding the effect of ST72 MRSA on the clinical outcome of MRSA infection\(^24,25\). Park et al.\(^23\) reported that ST72-SCCmeCIV was associated with reduced mortality compared with ST5-SCCmecII. In this study, 30-d and 12-week mortality did not differ over the study period. CVC-related infection, bone and joint infection, and infective endocarditis have been suggested as risk factors for bacteremia complication\(^26–28\). In the present study, there were no changes in CVC-related infection, bone and joint infection, and infective endocarditis, but the incidence of bacteremia complications, such as metastatic infection, persistent bacteremia, and recurrent bacteremia, decreased. In subgroup analysis, metastatic infection and recurrent bacteremia only decreased in community-onset infection. These results suggest changes in community-onset MRSA, and further research is warranted.

A high vancomycin MIC is associated with worse clinical outcomes and treatment failure\(^29–31\). Rybak et al.\(^32\) reported an increase in the vancomycin MIC of *S. aureus* from 1986 to 2007. The cell wall-active antibiotics inhibit bacterial growth by inhibiting peptidoglycan biosynthesis\(^33\). Molecular events of bacteria occur after treatment with cell wall-active antibiotics\(^34,35\). *S. aureus* activates a protective cell wall stress stimulons in response to the inhibition of cell envelope damage or cell wall synthesis caused by several antibiotics\(^34,36,37\). These factors probably increase the vancomycin MIC. In this study, the vancomycin MIC decreased over the 11-year study period, and the change was significant in HA infection. This may be due to the difference in the study period or study lesions. Additionally, there may be changes in microbiological and genomic factors of *S. aureus*. Further studies are necessary to assess changes in the microbiological and genomic factors of *S. aureus* that are associated with vancomycin MIC.

In Korea, resistance rates to clindamycin, erythromycin, ciprofloxacin, and gentamicin were lower in ST72-SCCmeCIV MRSA than in ST5-SCCmecII MRSA strain\(^22,23\). The resistance rate of ST72 MRSA to erythromycin was from 35.4% to 60.0%\(^22,23\). In this study, the erythromycin resistance rate of ST72 MRSA decreased only in community-onset infection. Several mechanisms cause erythromycin resistance to *S. aureus*; the presence of multicomponent macrolide efflux pumps (msrA, msrB) and enzymatic modification (EreA, EreB) of the antibiotics by enzymes\(^38–41\). In addition, macrolide resistance genes are present in erythromycin-resistant *S. aureus*\(^42\). Reduced use of macrolides or altered resistance genes of ST72 MRSA may contribute to decreased erythromycin resistance. Further studies are needed regarding changes in the mechanisms of erythromycin resistance.
Table 2. Univariate analysis of clinical and microbiological characteristics of 157 patients with sequence type 72 MRSA bacteremia.

| Characteristic                                      | 2008–2010 (n = 69) No. (%) | 2016–2018 (n = 88) No. (%) | p value |
|-----------------------------------------------------|-----------------------------|----------------------------|---------|
| Age (year), median (IQR)                            | 64 (55–72.5)                | 64.5 (52.3–74)             | 0.89    |
| Male                                                | 36 (52.2)                   | 56 (63.6)                  | 0.15    |
| Place of acquisition                                |                             |                            |         |
| Community-onset                                     | 35 (50.7)                   | 51 (58.0)                  | 0.42    |
| Community-acquired                                   | 9 (13.0)                    | 9 (10.2)                   | 0.58    |
| Healthcare-associated                               | 26 (37.7)                   | 42 (47.7)                  | 0.21    |
| Hospital-acquired                                    | 34 (49.3)                   | 37 (42.0)                  | 0.37    |
| Underlying disease                                  |                             |                            |         |
| Diabetes mellitus                                   | 30 (43.5)                   | 40 (45.5)                  | 0.81    |
| Solid tumor                                          | 25 (36.2)                   | 31 (35.2)                  | 0.90    |
| Liver cirrhosis                                      | 8 (11.6)                    | 15 (17.0)                  | 0.34    |
| End state renal disease                              | 10 (14.5)                   | 12 (13.6)                  | 0.88    |
| Charlson comorbidity index, median (IQR)            | 3 (2–5)                     | 2.5 (1–5)                  | 0.59    |
| APACHE II, median (IQR)                              | 16 (10.5–20)                | 16 (11–19.8)               | 0.88    |
| Pitt bacteremia score, median (IQR)                 | 1 (0–2)                     | 0 (0–2)                    | 0.69    |
| Septic shock                                        | 9 (13.0)                    | 9 (10.2)                   | 0.58    |
| Central venous catheter                              | 21 (30.4)                   | 28 (31.8)                  | 0.85    |
| Prosthetic device                                    | 10 (14.5)                   | 14 (15.9)                  | 0.81    |
| Characteristics of infection                        |                             |                            |         |
| CVC-related infection                                | 17 (24.6)                   | 16 (18.2)                  | 0.32    |
| Primary bacteremia                                   | 11 (15.9)                   | 12 (13.6)                  | 0.69    |
| Bone and joint infection                             | 7 (10.1)                    | 9 (10.2)                   | 0.99    |
| Skin and soft tissue                                 | 5 (7.2)                     | 10 (11.4)                  | 0.38    |
| Pneumonia                                            | 3 (4.3)                     | 11 (12.5)                  | 0.08    |
| Infective endocarditis                               | 5 (7.2)                     | 6 (6.8)                    | >0.99   |
| Metastatic infection                                 | 23 (33.3)                   | 15 (17.0)                  | 0.02    |
| Persistent bacteremia (≥ 3 d)                        | 38 (55.1)                   | 31 (35.2)                  | 0.01    |
| Recurrent bacteremia within 12 weeks                 | 8 (11.6)                    | 0                         | <0.01   |
| 30-d mortality                                       | 5 (7.2)                     | 13 (14.8)                  | 0.14    |
| 12-week mortality                                    | 14 (20.3)                   | 22 (25.0)                  | 0.49    |
| Infection-attributable mortality                     | 6 (8.7)                     | 16 (18.2)                  | 0.09    |
| In-hospital crude mortality                          | 8 (11.6)                    | 15 (17.0)                  | 0.34    |
| Vancomycin MIC (BMD), mean ± SD (mg/L)               | 1.11 ± 0.21                 | 1.03 ± 0.17                | <0.01   |
| agr dysfunction                                      | 6 (8.7)                     | 8 (9.1)                    | 0.93    |
| spa type                                             |                             |                            |         |
| t324                                                | 39 (56.5)                   | 36 (40.9)                  | 0.05    |
| t664                                                | 10 (14.5)                   | 10 (11.4)                  | 0.56    |
| t148                                                | 10 (14.5)                   | 11 (12.5)                  | 0.72    |
| Others                                               | 7 (10.1)                    | 16 (18.2)                  | NA      |
| Antibiotic resistance                               |                             |                            |         |
| Amoxicillin/Clavulanate                              | 67 (97.1)                   | 81 (92.0)                  | 0.30    |
| Clindamycin                                          | 12 (17.4)                   | 14 (15.9)                  | 0.80    |
| Ciprofloxacin                                        | 4 (5.8)                     | 10 (11.4)                  | 0.22    |
| Erythromycin                                         | 29 (42.0)                   | 14 (15.9)                  | <0.01   |
| Fusidic acid                                         | 0                          | 1 (1.1)                    | >0.99   |
| Gentamicin                                           | 11 (15.9)                   | 7 (8.0)                    | 0.12    |
| Rifampin                                             | 0                          | 2 (2.3)                    | 0.50    |
| Quinupristin/Dalfopristin                            | 0                          | 0                          | NA      |
| TMP/SMX                                              | 1 (1.4)                     | 0                          | 0.44    |
| Tetracycline                                         | 1 (1.4)                     | 2 (2.3)                    | >0.99   |
Table 3. Annual changes in the clinical and microbiological characteristics of 147 patients with community-onset infection. *A linear regression model was used for analysis. #Prosthetic device included orthopedic devices (8 patients), cardiovascular implantable electronic devices (1 patients), prosthetic valves (5 patients), and vascular grafts (24 patients) in patients with persistent bacteremia. ^Result of linear regression: R^2 = 0.025, vancomycin MIC = 22.07 + (−0.01) × year.

| Characteristic | Number of patients (%) | Annual change | RR (95% CI) | p value |
|---------------|------------------------|---------------|-------------|---------|
| Age (year), median (IQR) | 65 (54–73) | NA | NA | |
| Male | 92 (62.6) | NA | NA | |
| **Underlying disease** | | | | |
| Diabetes mellitus | 61 (41.5) | 0.99 (0.91–1.08) | 0.81 |
| Solid tumor | 48 (32.7) | 0.98 (0.89–1.08) | 0.67 |
| Liver cirrhosis | 18 (12.2) | 1.06 (0.91–1.24) | 0.47 |
| End state renal disease | 27 (18.4) | 0.96 (0.85–1.09) | 0.54 |
| Charlson comorbidity index, median (IQR) | 2 (1–4) | 0.04* | 0.56 |
| **APACHE II, median (IQR)** | 15 (11–19) | 0.01* | 0.97 |
| **Pitt bacteremia score, median (IQR)** | 0 (0–2) | 0.01* | 0.86 |
| **Septic shock** | 13 (8.8) | 0.92 (0.77–1.10) | 0.34 |
| **Central venous catheter** | 22 (15.0) | 1.03 (0.89–1.18) | 0.72 |
| **Prosthetic device** | 37 (25.2) | 0.96 (0.86–1.07) | 0.43 |
| **Characteristics of infection** | | | | |
| CVC-related infection | 15 (10.2) | 0.93 (0.79–1.10) | 0.41 |
| Primary bacteremia | 19 (12.9) | 1.08 (0.93–1.26) | 0.34 |
| Bone and joint infection | 22 (15.0) | 0.96 (0.84–1.10) | 0.54 |
| Skin and soft tissue | 22 (15.0) | 1.06 (0.92–1.22) | 0.44 |
| Pneumonia | 14 (9.5) | 1.08 (0.93–1.26) | 0.34 |
| Infective endocarditis | 10 (6.8) | 0.94 (0.77–1.15) | 0.55 |
| Metastatic infection | 36 (24.5) | 0.89 (0.80–0.99) | 0.04 |
| Persistent bacteremia (≥ 3 d) | 69 (46.9) | 0.94 (0.87–1.02) | 0.14 |
| Recurrent bacteremia within 12 weeks | 9 (6.1) | 0.64 (0.47–0.87) | 0.01 |
| 30-d mortality | 15 (10.2) | 1.10 (0.93–1.32) | 0.27 |
| 12-week mortality | 29 (19.7) | 1.00 (0.89–1.12) | 0.95 |
| Infection-attributable mortality | 21 (14.3) | 1.05 (0.91–1.21) | 0.49 |
| In-hospital crude mortality | 15 (10.2) | 1.08 (0.91–1.28) | 0.39 |
| Vancomycin MIC (BMD), mean ± SD (mg/L) | 1.10 ± 0.02 | −0.01* | 0.06 |
| agr dysfunction | 18 (12.2) | 0.99 (0.85–1.15) | 0.85 |
| SCCmec IV | 147 (100.0) | 1.00 (0.95–1.05) | >0.99 |
| SCCmec IVa | 129/147 (87.8) | 0.99 (0.94–1.05) | 0.81 |
| **spa type** | | | | |
| t324 | 67 (45.6) | 0.96 (0.89–1.04) | 0.35 |
| t664 | 20 (13.6) | 0.99 (0.86–1.14) | 0.90 |
| t148 | 19 (12.9) | 0.99 (0.86–1.15) | 0.95 |
| Others | 25 (17.0) | NA | NA | |
| **Antibiotic resistance** | | | | |
| Amoxicillin/Clavulanate | 139 (94.6) | 1.00 (0.95–1.06) | 0.97 |
| Clindamycin | 27 (18.4) | 0.99 (0.87–1.12) | 0.86 |
| Ciprofloxacin | 10 (6.8) | 1.06 (0.86–1.30) | 0.60 |
| Erythromycin | 38 (25.9) | 0.87 (0.78–0.96) | 0.01 |
| Fusidic acid | 1 (0.7) | NA | NA | |
| Gentamicin | 25 (17.0) | 0.92 (0.81–1.10) | 0.23 |
| Rifampin | 3 (2.0) | 1.24 (0.80–1.93) | 0.34 |
| Quinupristin/Dalfopristin | 0 | NA | NA | |
| TMP/SMX | 1 (0.7) | NA | NA | |
| Tetracycline | 4 (2.7) | 1.02 (0.74–1.41) | 0.91 |
| Characteristic                              | Number of patients (%) | Annual change RR (95% CI) | p value |
|--------------------------------------------|------------------------|---------------------------|---------|
| Age (year), median (IQR)                   | 62 (49.5–70.5)         | NA (NA)                   | NA      |
| Male                                       | 83 (57.2)              | NA (NA)                   | NA      |
| Underlying disease                         |                        |                           |         |
| Diabetes mellitus                          | 47 (32.4)              | 1.01 (0.92–1.11)          | 0.79    |
| Solid tumor                                | 59 (40.7)              | 1.04 (0.96–1.13)          | 0.37    |
| Liver cirrhosis                            | 24 (16.6)              | 1.10 (0.96–1.26)          | 0.16    |
| End stage renal disease                    | 14 (9.7)               | 1.09 (0.91–1.30)          | 0.34    |
| Charlson comorbidity index, median (IQR)   | 2 (2–5)                | 0.06*                     | 0.36    |
| APACHE II, median (IQR)                    | 16 (11–21)             | −0.04*                    | 0.85    |
| Pitt bacteremia score, median (IQR)        | 1 (0–2)                | −0.02*                    | 0.74    |
| Septic shock                               | 20 (13.8)              | 0.99 (0.86–1.15)          | 0.92    |
| Central venous catheter                    | 66 (45.5)              | 1.00 (0.92–1.08)          | 0.99    |
| Prosthetic device                          | 21 (14.5)              | 1.02 (0.89–1.18)          | 0.75    |
| Characteristics of infection               |                        |                           |         |
| CVC-related infection                      | 43 (29.7)              | 0.96 (0.86–1.06)          | 0.38    |
| Primary bacteremia                         | 23 (15.9)              | 0.91 (0.79–0.95)          | 0.19    |
| Bone and joint infection                   | 11 (7.6)               | 0.95 (0.78–1.16)          | 0.59    |
| Skin and soft tissue                       | 4 (2.8)                | 1.09 (0.79–1.52)          | 0.61    |
| Pneumonia                                  | 10 (6.9)               | 1.21 (0.97–1.52)          | 0.09    |
| Infective endocarditis                     | 4 (2.8)                | 1.19 (0.84–1.68)          | 0.32    |
| Metastatic infection                       | 21 (14.5)              | 0.88 (0.76–1.03)          | 0.11    |
| Persistent bacteremia (≥ 3 d)              | 47 (32.4)              | 0.93 (0.84–1.02)          | 0.12    |
| Recurrent bacteremia within 12 weeks       | 4 (2.8)                | 0.84 (0.59–1.20)          | 0.34    |
| 30-d mortality                             | 19 (13.1)              | 1.07 (0.92–1.24)          | 0.37    |
| 12-week mortality                          | 36 (24.8)              | 1.05 (0.94–1.17)          | 0.41    |
| Infection-attributable mortality           | 17 (11.7)              | 1.11 (0.94–1.30)          | 0.22    |
| In-hospital crude mortality                | 24 (16.6)              | 1.05 (0.92–1.19)          | 0.51    |
| Vancomycin MIC (BMD), mean ± SD (mg/L)     | 1.06 ± 0.01            | −0.01*                    | 0.03    |
| agr dysfunction                            | 13 (9.0)               | 1.05 (0.88–1.26)          | 0.57    |
| SCC mec type                               |                        |                           |         |
| SCC mec IV                                 | 144 (99.3)             | 1.00 (0.95–1.06)          | 0.95    |
| SCC mec IVa                                | 122/144 (84.7)         | 0.99 (0.93–1.05)          | 0.65    |
| spa type                                   |                        |                           |         |
| t324                                       | 72 (49.7)              | 0.97 (0.89–1.04)          | 0.37    |
| t664                                       | 22 (15.2)              | 0.93 (0.80–1.07)          | 0.30    |
| t148                                       | 14 (9.7)               | 0.95 (0.80–1.14)          | 0.60    |
| Others                                     | 24 (16.6)              | NA (NA)                   | NA      |
| Antibiotic resistance                      |                        |                           |         |
| Amoxicillin/Clavulanate                    | 132 (91.0)             | 1.01 (0.95–1.07)          | 0.78    |
| Clindamycin                                | 31 (21.4)              | 0.98 (0.87–1.01)          | 0.73    |
| Ciprofloxacin                              | 13 (9.0)               | 1.24 (1.02–1.52)          | 0.03    |
| Erythromycin                               | 37 (25.5)              | 0.91 (0.82–1.02)          | 0.10    |
| Fusidic acid                               | 2 (1.4)                | 1.16 (0.72–1.86)          | 0.56    |
| Gentamicin                                 | 14 (9.7)               | 0.99 (0.83–1.18)          | 0.92    |
| Rifampin                                   | 2 (1.4)                | 0.98 (0.61–1.55)          | 0.92    |
| Quinupristin/Dalfopristin                  | 0 NA                   | NA (NA)                   | NA      |
| TMP/SMX                                    | 1 (0.7)                | NA (NA)                   | NA      |
| Tetracycline                               | 4 (2.8)                | 1.12 (0.80–1.57)          | 0.50    |

Table 4. Annual changes in clinical and microbiological characteristics of 145 patients with hospital-acquired infection. *A linear regression model was used for analysis. †Prosthetic device included orthopedic devices (six patients), cardiovascular implantable electronic devices (three patients), prosthetic valves (six patients), and vascular grafts (six patients) in patients with persistent bacteremia. ‡Result of linear regression: $R^2 = 0.032$, vancomycin MIC = $21.57 + (−0.01) \times \text{year}$.  


This study has several limitations. First, this was a single-center study and our findings cannot be generalized to South Korea. Second, we evaluated ST72 MRSA types only, but analysis with other MRSA types, such as ST5 and ST239, may be helpful for understanding changes in S. aureus in Korea. However, this was the first large-scale study to analyze longitudinal changes in ST72 MRSA in Korea. This study will benefit future studies in the analysis of changes in S. aureus in community and nosocomial environments.

In conclusion, ST72 MRSA is an important pathogen in both community and nosocomial settings and its incidence increased over the 11-year study period. Bacteremia complication, vancomycin MIC, and resistance rate to erythromycin decreased, and these results suggest changes in the characteristics of ST72 MRSA. Further studies, including genome-wide studies, are needed to understand the reasons for changes of ST72 MRSA.

Data availability

The data of this study are available by contacting the corresponding author upon reasonable request.

Received: 29 April 2021; Accepted: 21 July 2021

Published online: 03 August 2021

References

1. DeLeo, F. R., Otto, M., Kreiswirth, B. N. & Chambers, H. F. Community-associated meticillin-resistant Staphylococcus aureus. Lancet 375, 1557–1566. https://doi.org/10.1016/S0140-6736(09)61999-1 (2010).

2. Song, J. H. et al. Spread of meticillin-resistant Staphylococcus aureus between the community and the hospitals in Asian countries: An ANSORP study. J. Antimicrob. Chemother. 66, 1061–1069. https://doi.org/10.1093/jac/dkt024 (2011).

3. Otter, J. A. & French, G. L. Community-associated meticillin-resistant Staphylococcus aureus strains as a cause of healthcare-associated infection. J. Hosp. Infect. 79, 189–193. https://doi.org/10.1016/j.jhin.2011.04.028 (2011).

4. Diekema, D. J. et al. Continued emergence of USA300 meticillin-resistant Staphylococcus aureus in the United States: Results from a nationwide surveillance study. Infect. Control Hosp. Epidem. 35, 285–292. https://doi.org/10.1086/675283 (2014).

5. Seybold, U. et al. Emergence of community-associated meticillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin. Infect. Dis. 42, 647–656. https://doi.org/10.1086/498815 (2006).

6. Kim, E. S. et al. A survey of community-associated meticillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 60, 1108–1114. https://doi.org/10.1093/jac/dkm309 (2007).

7. Park, C. et al. Predominance of community-associated meticillin-resistant Staphylococcus aureus strains carrying staphylococcal chromosome cassette mec type IVA in South Korea. J. Clin. Microbiol. 45, 4021–4026. https://doi.org/10.1128/jcm.01147-07 (2007).

8. Joo, E. J. et al. Community-associated Panton-Valentine leukocidin-negative meticillin-resistant Staphylococcus aureus clone (ST72-MRSA-IV) causing healthcare-associated pneumonia and surgical site infection in Korea. J. Hosp. Infect. 81, 149–155. https://doi.org/10.1016/j.jhin.2012.04.018 (2012).

9. Sung, J. Y., Lee, J., Choi, E. H. & Lee, H. J. Changes in molecular epidemiology of community-associated and health care-associated meticillin-resistant Staphylococcus aureus in Korean children. Diagn. Microbiol. Infect. Dis. 74, 28–33. https://doi.org/10.1016/j.diagmicrobio.2012.05.018 (2012).

10. Joo, E. J., Choi, J. Y., Chung, D. R., Song, J. H. & Ko, K. S. Characteristics of the community-genotype sequence type 72 meticillin-resistant Staphylococcus aureus isolates that underlie their persistence in hospitals. J. Microbiol. 54, 445–450. https://doi.org/10.1007/s12275-016-6157-x (2016).

11. Knaus, W. A., Draper, E. A., Wagner, D. P. & Zimmerman, J. E. APACHE II: A severity of disease classification system. Crit. Care Med. 13, 818–829 (1985).

12. Chow, J. W. et al. Enterobacter bacteremia: Clinical features and emergence of antibiotic resistance during therapy. Ann. Intern. Med. 115, 585–590. https://doi.org/10.7326/0003-4819-115-8-585 (1991).

13. Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of classifying prognostic combinations in longitudinal studies: Development and validation. J. Chronis Dis. 40, 373–383. https://doi.org/10.1016/0021-9681(87)90171-8 (1987).

14. Friedman, N. D., et al. Health care–associated bloodstream infections in adults: A reason to change the accepted definition of community-acquired infections. Ann. Intern. Med. 137, 791–797. https://doi.org/10.7326/0003-4819-137-10-200211190-00007 (2002).

15. Mermel, L. A. et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the infectious diseases Society of America. Clin. Infect. Dis. 49, e1–e45. https://doi.org/10.1086/599176 (2009).

16. Li, J. S. et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin. Infect. Dis. 30, 633–638. https://doi.org/10.1086/313753 (2000).

17. Singer, M. et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315, 801–810. https://doi.org/10.1001/jama.2016.2827 (2016).

18. Enright, M. C., Day, N. P., Davies, C. E., Peacock, S. J. & Spratt, B. G. Multilocus sequence typing for characterization of meticillin-resistant and meticillin-susceptible clones of Staphylococcus aureus. J. Clin. Microbiol. 38, 1008–1015 (2000).

19. Oliveira, D. C. & de Lencastre, H. Multiplex PCR strategy for rapid identification of structural types and variants of the mec element in meticillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 46, 2153–2161. https://doi.org/10.1128/aac.46.7.2155-2161.2002 (2002).

20. Shopsin, B. et al. Prevalence of agr specificity groups among Staphylococcus aureus strains colonizing children and their guardians. J. Clin. Microbiol. 41, 456–459. https://doi.org/10.1128/jcm.41.5.456-459.2003 (2003).

21. Schweizer, M. L. et al. Increased mortality with accessory gene regulator (agr) dysfunction in Staphylococcus aureus among bacteremic patients. Antimicrob. Agents Chemother. 55, 1082–1087. https://doi.org/10.1128/aac.00918-10 (2011).

22. Park, S. H. et al. Emergence of community–associated meticillin-resistant Staphylococcus aureus strains as a cause of healthcare-associated bloodstream infections in Korea. Infect. Control Hosp. Epidem. 30, 146–153. https://doi.org/10.1086/593953 (2009).

23. Park, K. H. et al. Community-associated MRSA strain ST72-SCmecIV causing bloodstream infections: Clinical outcomes and bacterial virulence factors. J. Antimicrob. Chemother. 70, 1185–1192. https://doi.org/10.1093/jac/dka475 (2015).

24. Chong, Y. P. et al. Persistent Staphylococcus aureus bacteremia: A prospective analysis of risk factors, outcomes, and microbiologic and genotypic characteristics of isolates. Medicine (Baltimore) 92, 98–108. https://doi.org/10.1097/MD.0000000000001891 (2013).

25. Jung, H. C. et al. Difference in agr dysfunction and reduced vancomycin susceptibility between MRSA bacteria involving SCmec types IV/Iva and I-III. PLoS ONE 7, e94136. https://doi.org/10.1371/journal.pone.0094136 (2012).

26. Hawkins, C. et al. Persistent Staphylococcus aureus bacteremia: An analysis of risk factors and outcomes. Arch. Intern. Med. 167, 1861–1867. https://doi.org/10.1001/archinte.167.17.1861 (2007).

27. Lee, Y. M. et al. Long-term meticillin-resistant Staphylococcus aureus bacteremia persisting for more than 2 weeks: Risk factors and outcomes. Eur. J. Clin. Microbiol. Infect. Dis. 39, 773–781. https://doi.org/10.1007/s10096-019-03795-6 (2020).
28. Chang, E.Y. et al. *Staphylococcus aureus* bacteremia: Recurrence and the impact of antibiotic treatment in a prospective multicenter study. *Medicine (Baltimore)* **82**, 333–339. https://doi.org/10.1097/01.md.00000918439312.09 (2003).

29. Bae, I. G. et al. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant *Staphylococcus aureus* isolates from an international cohort of patients with infective endocarditis: Prevalence, genotype, and clinical significance. *J. Infect. Dis.* **200**, 1355–1366. https://doi.org/10.1086/606027 (2009).

30. Kullar, R., Davis, S. L., Levine, D. P. & Rybak, M. J. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant *Staphylococcus aureus* bacteremia: Support for consensus guidelines suggested targets. *Clin. Infect. Dis.* **52**, 975–981. https://doi.org/10.1093/cid/cir124 (2011).

31. Lodise, T. P. et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant *Staphylococcus aureus* bacteremia treated with vancomycin. *Antimicrob. Agents Chemother.* **52**, 3315–3320. https://doi.org/10.1128/aac.00113-08 (2008).

32. Rybak, M. J. et al. Characterization of vancomycin-heteroresistant *Staphylococcus aureus* from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). *J. Clin. Microbiol.* **46**, 2950–2954. https://doi.org/10.1128/JCM.00582-08 (2008).

33. Gale, E. F., Cundliffe, E., Reynolds, P. E., Richmond, M. H. & Waring, M. T. *The Molecular Basis of Antibiotic Action* (2nd edn. Wiley, New York, 1982).

34. Utaida, S. et al. Genome-wide transcriptional profiling of the response of *Staphylococcus aureus* to cell-wall-active antibiotics reveals a cell-wall-stress stimulon. *Microbiology (Reading)* **149**, 2719–2732. https://doi.org/10.1099/mic.0.26426-0 (2003).

35. Boyle-Vavra, S., Yin, S., Challapalli, M. & Daum, R. S. Transcriptional induction of the penicillin-binding protein 2 gene in *Staphylococcus aureus* by cell-wall-active antibiotics oxacillin and vancomycin. *Antimicrob. Agents Chemother.* **47**, 1028–1036. https://doi.org/10.1128/AAC.47.3.1028-1036.2003 (2003).

36. Jordan, S., Hutchings, M. I. & Mascher, T. Cell envelope stress response in Gram-positive bacteria. *FEMS Microbiol. Rev.* **32**, 107–146. https://doi.org/10.1111/j.1574-6976.2007.00091.x (2008).

37. Kuroda, M. et al. Two-component system VraSR positively modulates the regulation of cell-wall biosynthesis pathway in *Staphylococcus aureus*. *Mol. Microbiol.* **49**, 807–821. https://doi.org/10.1046/j.1365-2958.2003.03599.x (2003).

38. Sutcliffe, J., Grebe, T., Tait-Kamradt, A. & Wondrak, L. Detection of erythromycin-resistant determinants by PCR. *Antimicrob. Agents Chemother.* **40**, 2562–2566. https://doi.org/10.1128/AAC.40.11.2562 (1996).

39. Ross, J. I., Eady, E. A., Cove, J. H. & Baumberg, S. Identification of a chromosomally encoded ABC-transport system with which the staphylococcal erythromycin exporter MsrA may interact. *Gene* **153**, 93–98. https://doi.org/10.1016/S0378-1119(94)00833-e (1995).

40. Wondrak, L., Massa, M., Yang, B. V. & Sutcliffe, J. Clinical strain of *Staphylococcus aureus* inactivates and causes efflux of macrolides. *Antimicrob. Agents Chemother.* **40**, 992–998. https://doi.org/10.1128/AAC.40.4.992 (1996).

41. Milton, I. D., Hewitt, C. L. & Harwood, C. R. Cloning and sequencing of a plasmid-mediated erythromycin resistance determinant from *Staphylococcus xylosus*. *FEMS Microbiol. Lett.* **76**, 141–147. https://doi.org/10.1016/0378-1097(92)90377-x (1992).

42. Schmitz, F. J. Distribution of macrolide-resistance genes in *Staphylococcus aureus* blood-culture isolates from fifteen German university hospitals. M.A.R.S. Study Group Multicentre Study on Antibiotic Resistance in Staphylococci. *Eur. J. Clin. Microbiol. Infect. Dis.* **19**, 385–387. https://doi.org/10.1007/s10096-005-0500 (2000).

Acknowledgements
We sincerely thank BO MIN KWON and Kyeongmi Lee for their support with the data collection.

Author contributions
All authors contributed to the study conception and design of the study. Data collection was performed by E.M.Y., E.S.K., H.M.C., Y.W.L., and S.M.B. E.M.Y. analyzed the data and drafted the manuscript. J.W.J., M.J.K., Y.P.C., and approved the final manuscript.

Funding
This work was supported by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea [grant number HI15C2918].

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to Y.S.K.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021